Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: A multicentre study

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 305-311

  Barinoff, J ^a,b   Hils, R ^b   Bender, A ^c   Gross J ^d   Kurz, C ^e   Tauchert, S ^f   Mann, E ^g   Schwidde, I ^a   Ipsen, B ^h   Sawitzki, K ⁱ   Heitz, F ^a,b   Harter, P ^a,b   Traut, A ^a,b   Du Bois, A ^a,b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c Asklepios Klinik   (Germany)

^d Sankt Gertrauden Krankenhaus   (Germany)

^e KLINIKUM ESSLINGEN   (Germany)

^f Caritasklinik St Theresia   (Germany)

^g UNIVERSITY HOSPITAL MARBURG   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

Primary metastatic breast cancer; Prognostic factors; Stage IV breast cancer; Synchronous metastases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CENTER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84872121206     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.027     Document Type: Article

References (26)

1. Krebs in Deutschland 2003-2004 Häufigkeit und Trends. Robert Koch Institut. 6. Überarbeitete Auflage, 2008.
2. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592
3. C. Smigal, A. Jemal, and E. Ward Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin Oncol 56 2006 168 183
4. A.M. Brewster, G.N. Hortobagi, and K.R. Brogilo Residual risk of breast cancer recurrence 5 years after adjuvant therapy J Natl Cancer Inst 100 2008 1179 1183
5. D. Schön, J. Bertz, and B. Görsch Die Dachdokumentation Krebs Gesundheitsbl Gesundheitsforsch Gesundheitsschutz 47 2004 429 436
6. G.M. Clark, G.W. Sledge Jr., C.K. Obsorne, and W.L. McGuire Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients J Clin Oncol 5 1987 55 61
7. Ries LAG, Eisner MP. Cancer of the female breast. In: Ries LAG, Keel GE, Eisner MP, et al., editors. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics, 07-6215. Bethesda, MD, National Cancer Institute, NIH; 2007. p. 101-10.
8. E.L. Mayer, and H.J. Burstein Chemotherapy for metastatic breast cancer Hematol Oncol Clin North Am 21 2007 257 272
9. F. Andre, and K. Slimane Breast cancer with synchronous metastases: trends in survival during a 14-year period J Clin Oncol 16 2004 3302 3308
10. J.R. Harris, M. Morrow, and G. Bonnadona Cancer of the breast De Vita Jr. S. Hellman, S.A. Rosenberg, Cancer. Principles and practice in oncology 2nd ed. 1993 JB Lippincott Philadelphia, PA 1264 1332
11. K.D. Miller, and G.W. Sledge Jr. The role of chemotherapy for metastatic breast cancer Hematol Onco Clin Narth Am 13 1999 415 434
12. J. Barinoff, F. Heitz, P. Harter, F. Lorenzs-Salehi, A. Traut, and A. du Bois Primär metastasierendes Mammakarzinom: Gesamtüberleben im zeitlichen Verlauf Senologie 6 2009 177 194 abstr. 12
13. D. Hölzel, J. Engel, M. Schmidt, and H. Sauer Modell zur pirmären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung Strahlenther Onkol 1 2001 10 24
14. D. Ali, and R. Le Scodan Treatment of the primary tumor in breast cancer patients with synchronous metastases Ann Oncol 22 2011 9 16
15. M.F. Blows, K.E. Driver, and M.K. Schmidt Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of date for 10,159 cases from 12 studies PLoS Med 7 2010 e10000279
16. Ruiterkamp J, Ernst F.M. The role of surgery in metastatic breast cancer. The European multidisciplinary cancer congress, Stockholm, 23-27 September 2011.
17. R. Le Scodan, D. Stevens, and E. Brain Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy J Clin Oncol 27 2009 1375 1381
18. C.L. Carter, C. Allen, and D.E. Henson Relation of tumor size, lymph node status, and survival in 24.740 breast cancer cases Cancer 63 1989 181
19. Kawano A, Shimizu C, Hashimoto K, et al. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. Breast Cancer, publ. online 03 December 2011.
20. J. Gnerlich, D.B. Jeffe, and A.D. Deshpande Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1998-2003 SEER data Ann Surg Oncol 14 8 2007 2187 2194
21. T.N. Pathiraja, P.B. Shetty, and J. Jelinek Progesterone receptor isoform-specific promoter methylation: association of PRA with worse outcome in breast cancer patients Clin Cancer Res 17 12 2011 4177 4186
22. X. Cui, R. Schiff, G. Arpino, C.K. Osborne, and A.V. Lee Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 2005 7721 7735
23. M. De Laurentiis, G. Arpino, and A. Massarelli A meta-analysis on the interaction between Her-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 313 2005 4741 4750
24. G. Arpino, L. Wiechmann, C.K. Osborne, and R. Schiff Crosstalk between the oestrogen receptor and the Her tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 2 2008 217 233
25. G. Bogina, L. Bortesi, and M. Marconi Comparison of hormonal receptor and Her-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss Virchows Arch 459 1 2011 1 10
26. S. Dawood, K. Broglio, J. Ensor, G.N. Hortobagy, and S.H. Giordano Survival differences among women with de novo stage IV and relapsed breast cancer Ann Oncol 21 2010 2169 2174